# NHSN Surveillance for Urinary Tract Infections (UTI) and Multidrug-Resistant Organisms (MDRO) in Long-Term Care Facilities

Wisconsin Division of Public Health September—October 2016

# **Objectives**



- Provide an overview of HAI surveillance in LTC facilities
- Discuss the LTC UTI surveillance protocol and UTI case definitions
- Present UTI case studies to demonstrate practical applications of case definitions



# Overview of LTC Surveillance Definitions

3

# Overview: LTC Surveillance Definitions



- First developed in 1991 by McGeer et al.
- Modified from CDC acute care definitions
- Provide standardized definitions for benchmarking and research activities
- Updated version published in 2012
- Consensus obtained from infectious disease physicians, geriatricians, infection prevention nurses

• Evidence-based review of literature



# Overview: LTC Surveillance Definitions

- Intended for use in LTC facilities among older adults who require care for impaired cognition, assistance with activities of daily living or skilled nursing care
- Not designed for use in long-term care hospitals, inpatient rehabilitation facilities or pediatric LTC facilities

E



# Overview: LTC Surveillance Definitions

# Guiding principles:

- Specificity: Increase likelihood that identified events are true healthcare-associated infections (HAIs).
- Sensitivity: Definitions may not be adequate for real-time case finding, diagnosis or clinical decision-making.
- Surveillance is targeted toward identifying preventable events or those with high risk of transmission.

(



# Overview: LTC Surveillance Definitions

- HAIs are those with no evidence of incubation at time of admission to facility, and onset of symptoms occurs > 2 calendar days after admission.
- Diagnosis by a physician alone is not sufficient to meet surveillance definitions.

6

# Overview: LTC Surveillance Definitions



# Consider the following when applying surveillance definitions:

- All symptoms must be new or acutely worse.
- Alternate noninfectious causes should be considered.
- Identification of an infection should not be based on a single piece of evidence but should also include clinical presentation and available microbiological and radiologic information.





#### Constitutional criteria

- Standardized definitions for fever, acute change in mental status and acute functional decline are provided.
- Criteria are consistent with 2008 Infectious Disease Society of America guidelines.
- New lower threshold for fever increases sensitivity.
- Standardizes assessment of mental status and functional change using Minimum Data Set scoring system.

g



# **SHEA/CDC Position Paper**

Stone ND, Ashraf MS, Calder J, et al. Surveillance definitions in long-term care facilities: Revisiting the McGeer criteria. *Infect Control Hosp Epidemiol* 2012;33(10):965-977.

SHEA = Society for Healthcare Epidemiology of America



# **Surveillance for UTI**

11



# **Background**

- 20-30% of reported HAIs among LTC residents are UTIs.
- UTI prevalence is estimated at 25-50%, and accounts for large amount of antibiotic use.
- Risk factors
  - Age-related changes in the urinary tract
  - Co-morbid conditions resulting in neurogenic bladder
  - Instrumentation required to manage bladder voiding



# **Background**

- Complications of catheter-associated urinary tract infections (CAUTI) include functional decline, bacteremia, septic shock, increased mortality.
- 2009 CDC Guideline for the Prevention of CAUTI can be accessed at

http://www.cdc.gov/hicpac/cauti/002\_cauti\_toc.
html

13



# **Background**

- UTI protocol is designed for
  - Certified skilled nursing facilities/nursing homes.
  - Intermediate/chronic care facilities for the developmentally disabled.
- Surveillance should be done facility-wide.
- For residents transferred from an acute care facility: Signs/symptoms within first 2 calendar days of admission are considered present at time of transfer and should be reported back to the transferring facility.



# **UTI Surveillance Protocol**

Signs/symptoms of infection occurring within 2 calendar days of admission (date of admission is day 1) are considered present on admission and are not HAIs.

Example: Classification of HAI Events					
Admission date					
June 4	June 5	June 6	June 7	June 8	
Day 1	Day 2	Day 3	Day 4	Day 5	
POA—not an H	IAI	ı	Potential HAI		

15



# **UTI Surveillance Protocol**

- A positive urine culture is necessary for diagnosis of UTI and is required for both CAUTI and non-CAUTI events.
- Voided specimen: need at least 100,000 (10<sup>5</sup>) CFU/ml of microorganisms, no more than 2 species, at least one of which is bacteria.
- Indwelling catheter: need at least 100,000 (10<sup>5</sup>)
   CFU/ml of any microorganisms, at least one of which is bacteria.
- If collected by in and out catheter: need at least 100 (10<sup>2</sup>) CFU/ml of any number of organisms, at least one of which is bacteria.



## **UTI Surveillance Protocol**

- Before urine samples for culture are obtained from residents with chronic catheters (in place for more than 14 days) the original catheter should be replaced and specimen obtained from the new catheter.
- Repeat cultures, or "tests of cure" are not recommended.

17



# **UTI Definitions**

- Date of event: date when the first clinical evidence (signs/symptoms) of the UTI appeared, OR, the date of specimen collection, whichever comes first.
- Symptomatic UTI (SUTI): resident has signs/symptoms localized to the urinary tract (e.g., acute dysuria, new/marked increased frequency, suprapubic tenderness).



# **UTI Definitions**

 CA-SUTI: resident develops signs/symptoms localized to urinary tract while indwelling catheter is in place, OR, removed within the 2 calendar days prior to the date of the event (where day of catheter removal is day 1).

Note: catheter must be in place for a minimum of 2 calendar days prior to onset of infection (date of event).

19

# **UTI Definitions**



June 1	June 2	June 3	June 4	June 5	June 6	June 7
Day 1 insertion	Day 2 insertion	Day 3 insertion	Day 1 removal	Day 2 removal	Day 3 removal	Day 4 removal
Not CA-SU days	TI event	Potential C	CA-SUTI ev	ent days	Not an event day	Not an event day



#### **UTI Definitions**

- Indwelling urinary catheter: a drainage tube that is inserted into the urinary bladder through the urethra, is left in place, and is connected to a closed collection system (also called a Foley catheter).
- Straight in and out, condom and suprapubic catheters are not indwelling catheters.

Note: UTIs in residents managed with nonindwelling catheters will be considered SUTIs, not CA-SUTIs.

21



# **UTI Definitions**

Asymptomatic bacteremic UTI (ABUTI): resident has *no* signs/symptoms localizing to the urinary tract but has urine and blood cultures positive for at least one matching organism, whether or not a catheter is in place.




# **Examples of Matching Organisms**


Culture	Companion culture	Report as
Staphylococcus epidermidis	Coagulase-negative staphylococci	S. epidermidis
Klebsiella oxytoca	Klebsiella spp.	K. oxytoca
Streptococcus salivarius	Strep viridans	S. salivarius

23

# **LTCF UTI Protocol 2016 Updates**

- Presence of a fever, even if due to another cause, should be counted as part of meeting the surveillance definition of a UTI.
- Yeast and other non-bacterial microorganism are no longer considered UTI-associated pathogens.
- Addition to denominator data: new antibiotic starts for UTI indication.





	Resident with <u>or without</u> an indwelling catheter: ABUTI Criteria
	as no localizing urinary signs or symptoms (i.e., no urgency, frequency, acute dysuria, suprapubic tendemess, or costovertebral pain or tendemess). If no catheter is in place, fever as only sign would not exclude ABUTI if other positive culture criteria are met.
	AND
Spector     bacte     Spector     CFU	imen collected from indwelling catheter and positive culture with any microorganism, at least one of which is bacteria of $\geq 10^5$
	AND  Positive blood culture with at least 1 matching organism in urine culture  ABUTI

Facility ID:		Event		
Resident ID:			Security #:	
Medicare number (or comparable railro		ber):	1070	
Resident Name, Last: Gender: M F Other	First:	*Date	Middle of Birth: / /	
Ethnicity (specify):			specify):	
☐ Long-term general nursing ☐ Skilled nursing/Short-term rehab (	E-22/22/24	□ Ventilator	☐ Long-term psy	☐ Hospice/Palliative
Has resident been transferred from an If Yes, date of last transfer from acu	te care to your faci	ility: _/_/		
If Yes, did the resident have an indw Indwelling Urinary Catheter status at ti			it transfer to your faci	lity? ☐ Yes ☐ No
indivening Officery Catheter Status at the	the of event onset	(cirech one).		

Inserted (ch	indwelling urinary catheter	☐ Acute care hospital ☐ Other ☐ Unknown		
If indwelling urin	ary catheter not in place, was another urinary device	type present at the time of event onset? $\ \ \square$ Yes $\ \ \square$ No		
	r device type:   Suprapubic   Condom (ma	les only)   Intermittent straight catheter		
Event Details	tr (about all that annity)			
Specify Citteria Oseo	l: (check all that apply) Signs & Symptoms	Laboratory & Diagnostic Testing		
	perature ≥ 37.8°C (>100°F), or > 37.2°C (>99°F) on s, or an increase of >1.1°C (>2°F) over baseline	Specimen collected from clean catch voided urine and positive culture with ≥ 10 <sup>5</sup> CFU/ml of no more than 2 species of microorganisms     Specimen collected from in/out straight catheter and positive culture with ≥ 10 <sup>2</sup> CFU/ml of any microorganisms     Specimen collected from indwelling catheter and		
☐ Rigors	□ New onset hypotension			
□ New onset confusi	on/functional decline			
<ul> <li>Acute pain, swellin prostate</li> </ul>	g, or tenderness of the testes, epididymis, or			
☐ Acute dysuria	☐ Purulent drainage at catheter insertion site			
New and/or m	narked increase in (check all that apply):	positive culture with ≥ 10 <sup>5</sup> CFU/ml of any microorganisms		
☐ Urgency	☐ Costovertebral angle pain or tenderness	Leukocytosis (> 14,000 cells/mm³), or Left shift (> 6% 1,500 bands/mm³)		
☐ Frequency	☐ Suprapubic tenderness			
☐ Incontinence	☐ Visible (gross) hematuria	☐ Positive blood culture with 1 matching organism in urin culture		

Pathogen #	Gram-positive Organisms								
-	Staphylococcus coagulase-negative (specify species if available):		VANC SIRN						
	Enterococcu Enterococcu (Only those no species level)	is faecalis is spp.		DAPTO S NS N	GENTHL <sup>§</sup> SRN	LNZ SIRN	VANC SIRN		
	Staphylococcus aureus	CIPRO/LI SIRN OX/CEFO SIRN	EVO/MOXI DX/METH	CLIND SIRN RIF	DAPTO S NS N TETRA	DOXY/MINO SIRN TIG	ERYTH SIRN TMZ	GENT SIRN VANC	LNZ SRN
Pathogen #	Gram-negative C	s	SIRN	SIRN	SNSN	SIRN	SIRN		
	Acinetobacter (specify species)	AMK SIRN	AMPSUL SIRN	AZT SIRN	CEFEP	CEFTAZ SIRN	CIPRO/LEVO SIRN		COL/PB SIRN
		GENT SIRN	SIRN	MERO/D SIRN	ORI	PIP/PIPTAZ SIRN		TETRA/D SIRN	OXY/MINO
		TMZ	TOBRA						



# **UTI Denominator Data**

#### Catheter-days

 Defined as the number of residents with an indwelling urinary catheter; collected daily for all residents in the facility and totaled at the end of the month.

#### Resident-days

 Calculated using the daily census of residents in the facility each day of the month and totaled at the end of the month.

Note: If a resident is transferred to an acute care facility for a suspected UTI, no additional indwelling catheter days are counted after the day of transfer.



# **UTI Denominator Data**

#### New antibiotic starts for UTI indication.

- May be collected daily or summarized at end of month
- New prescription for an antibiotic ordered for a resident suspected or diagnosed with a UTI regardless of whether the UTI meets the NHSN definition
- No minimum doses or days of therapy required to count include all new orders
- Include only antibiotics started while resident is receiving care in your facility, either by facility providers or outside ER or outpatient physicians
- Antibiotics started by another facility prior to admission or readmission are not included

		Denom	inators for l	LICE	
Page 1 of 1 Facility ID		*Location Code:		*Month:	*required for savi
Date	*Number of residents	*Number of residents with a urinary catheter	*New antibiotic starts for UTI indication	*Number of admissions	Number of admissions on C. diff treatment
1					
2					
3					
4					
5					
6					
7					
8					
9					
10					
11					
31					
*Total					
	Resident-days	Urinary-catheter days	Total antibiotic starts for UTI indication	Resident- admissions	Resident- admissions on C diff treatment

# San of Washington

# **UTI Data Calculations**

# Total UTI incidence rate/1,000 resident-days

number of UTI events (SUTI + CA-SUTI + ABUTI)/total resident-days x 1,000

- % SUTI = number of SUTI events/total number of UTI events x 100
- % CA-SUTI = number of CA-SUTI events/total number of UTI events x 100
- % ABUTI = number of ABUTI events/total number of UTI events x 100



# **UTI Data Calculations**

# SUTI incidence rate/1,000 resident-days

number of SUTI events/total residentdays minus total catheter-days x 1,000

These events are not catheter-associated.

35



# **UTI Data Calculations**

# CA-SUTI incidence rate/1,000 catheter-days

number of CA-SUTI events/total catheterdays x 1,000

Only symptomatic events which develop at the time an indwelling catheter is in place or recently removed (within last 2 calendar days) will contribute to the CA-SUTI rate.



# **UTI Data Calculations**

# Urinary catheter utilization ratio

total urinary catheter-days/total resident-days

37



# **UTI Data Calculations**

#### **UTI** treatment ratio

new antibiotic starts for UTI/total UTI count (SUTI + ABUTI + CA-SUTI)



# Links

#### **NHSN LTC UTI protocol**

http://www.cdc.gov/nhsn/pdfs/ltc/ltcf-uti-protocol-current.pdf

#### **NHSN UTI event form**

http://www.cdc.gov/nhsn/forms/57.140\_uti\_ltcf\_blank.pdf

#### **NHSN** denominator form

http://www.cdc.gov/nhsn/forms/57.142 denominatorItcf blank.pdf

#### **NHSN Table of Instructions**

http://www.cdc.gov/nhsn/forms/instr/57.140-toi-uti-toi\_final.pdf

39



# **UTI Module Test Questions**

#### Question 1:

Incidence for symptomatic urinary tract infections (SUTI) is calculated using:

- A. Total number of SUTIs for a given time period in the numerator and total number of resident-days for the same time period in the denominator.
- B. Total number of SUTIs for a given time period in the denominator and total number of resident-days for the same time period in the numerator.
- C. Total number of SUTIs for a given time period in the numerator and total number of resident-days minus the total number of indwelling catheter-days for the same time period in the denominator.
- D. Total number of SUTIs and catheter-associated UTIs for a given time period in the numerator and total number of indwelling catheter-days for the same time period in the denominator.



# **UTI Module Test Questions**

#### **Question 2:**

Which of the following is true regarding the 2016 UTI protocol for long-term care facilities?

- A. Presence of a fever is no longer a part of the UTI surveillance definition.
- B. Yeast and other non-bacterial microorganisms are no longer considered UTI-associated pathogens.
- c. The date of event is now considered the first date when ALL signs and symptoms that meet the UTI surveillance definition are present.
- D. A and B

41

# Surveillance for MDRO



# **Background**

#### MDRO module includes surveillance for

- C. difficile infections (CDI)
- Methicillin sensitive *S. aureus* (MSSA)
- Methicillin-resistant *S. aureus* (MRSA)
- Vancomycin-resistant Enterococcus spp. (VRE)
- Cephalosporin-resistant Klebsiella spp.
- Carbapenem-resistant E. coli and Klebsiella spp. (CRE)
- Multidrug-resistant Acinetobacter spp.

43



# **Background**

- A large proportion of LTC residents are at risk for MDRO carriage; infections with MDRO are associated with increased lengths of stay, hospitalizations, readmissions, healthcare costs and mortality.
- Both MDRO and CDI prevalence is increasing.
- CDC Threat Report 2013: <a href="http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf">http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf</a>



# **Background**

- Purpose of CDI/MDRO protocol is to enable facilities to collect, report and analyze data that will inform infection prevention strategies.
- Two components of the protocol:
  - CDI
  - MDRO
- Protocols based on laboratory test data to be used without clinical evaluation of the resident.
- Data are collected facility-wide.

45



# **Prevention Resources**

- APIC Guide to the Elimination of MRSA
   Transmission in Hospital Settings, 2<sup>nd</sup> Edition.

   <a href="http://www.apic.org/Resource\_/EliminationGuideForm/631fcd9">http://www.apic.org/Resource\_/EliminationGuideForm/631fcd9</a>

   <a href="http://www.apic.org/resource\_/EliminationGuideForm/631fcd9">http://www.apic.org/resource\_/EliminationGu
- APIC Guide to Preventing C. difficile Infections
   http://www.apic.org/Resource\_/EliminationGuideForm/59397fc6
   -3f90-43d1-9325-e8be75d86888/File/2013CDiffFinal.pdf



# **Prevention Resources**

• CDC Management of MDRO in Healthcare Settings, 2006.

http://www.cdc.gov/hicpac/pdf/MDRO/MDROGuideline2006.pdf

- DPH Guidelines for Prevention and Control of Antibiotic Resistant Organisms in Healthcare Settings, 2005. http://www.dhs.wisconsin.gov/publications/P4/P42513.pdf
- DPH Guidance for Prevention of Transmission of CRE in Skilled Nursing Facilities

https://www.dhs.wisconsin.gov/publications/p0/p00532.pdf



# **CRE Surveillance Protocol**

- Laboratory-based, with no clinical evaluation of the resident.
- Surveillance is conducted facility-wide.

48




## **CRE Definition**

CRE: Any Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae, or Enterobacter spp. determined to produce a carbapenemase (i.e., KPC, NDM, VIM, IMP, OXA-48) using a recognized test (e.g., polymerase chain reaction, metallo-β-lactamase test, modified-Hodge test, Carba-NP).

Source: National Healthcare Safety Network (NHSN)

49

#### Laboratory-identified MDRO Event in LTCF NHSN LTCF MDRO/C. difficile protocol http://www.cdc.gov/nhsn/PDFs/LTC/LTCF-LabID-Event-Protocol\_FINAL\_8-24-12.pdf Resident name \_ Date of admission\_\_\_\_ Date of previous MDRO Record number\_ culture result\_\_ \_Date of event\_\_\_ \_\_\_\_\_ (date of specimen collection) Date of review MDRO laboratory-identified event (MDRO LabID) Individual is receiving care at the LTCF at time of specimen collection AND □ Specimen is collected for clinical assessment purposes (not active surveillance testing) One of the following definitions of a unique laboratory event is met ☐ MDRO isolate is the first one obtained in the calendar month from any specimen source (e.g., urine, wound, sputum, blood) for the resident (if source is blood, a prior positive blood culture with the same MDRO must not occur ≤14 days before the current blood culture, even if in different calendar months) ☐ MDRO isolate the first obtained from a blood source in the calendar month (with no prior positive blood culture with the same MDRO ≤14 days before the current blood culture). A prior MDRO may or may not have been obtained from another source (e.g., urine, wound, sputum)



# **CRE Denominator Data**



# Resident-days

 Calculated using the daily census of residents in the facility each day of the month and totaled at the end of the month.



# **CRE Data Calculations**

#### **Total CRE rate**

number of CRE LabID events per month/number of resident-days per month x 1,000

53



# **CRE Response**

- Report to DPH HAI Prevention Program.
- Follow DPH CRE response protocol in the nursing home toolkit.
- DPH CRE webpage <a href="http://www.dhs.wisconsin.gov/communicable/ARO/C">http://www.dhs.wisconsin.gov/communicable/ARO/C</a>
   <a href="https://www.dhs.wisconsin.gov/communicable/ARO/C">RE.htm</a>
- DPH CRE toolkit for skilled nursing facilities <a href="https://www.dhs.wisconsin.gov/publications/p0/p">https://www.dhs.wisconsin.gov/publications/p0/p</a>

   00532.pdf



# **CRE Report**

http://www.dhs.wisconsin.gov/publications/P0/P00578.pdf

5



# Links

# **NHSN MDRO/CDI protocol**

http://www.cdc.gov/nhsn/PDFs/LTC/LTCF-LabID-Event-Protocol\_FINAL\_8-24-12.pdf

#### **NHSN** denominator form

http://www.cdc.gov/nhsn/PDFs/LTC/forms/57.142\_ DenominatorLTCF\_BLANK.pdf

#### **DPH MDRO/CDI surveillance worksheet**

http://www.dhs.wisconsin.gov/communicable/HAI/ Worksheets/LTCFMDROCdiff.pdf



# **Surveillance for CDI**

57



# **CDI Surveillance**

- Report positive C. difficile laboratory assays obtained from any resident receiving care at the facility.
- Do not include tests obtained when the resident was not admitted to the facility.
- Number of resident admissions and number of resident-days are recorded for each month.
- Testing should be done only on liquid or watery stool samples (i.e., conforming to the shape of the container).



## **CDI Definitions**

- C. difficile positive laboratory assay: a positive result for C. difficile toxin A or B by enzyme immunoassay (EIA), OR, a toxin-producing organism detected in the stool by culture or other laboratory means (nucleic acid amplification testing by PCR)
- Duplicate C. difficile positive laboratory assay: any
  C. difficile positive test from the same resident
  following a previous positive test within the past two
  weeks

59



# **CDI Definitions**

CDI laboratory-identified (LabID) event: all nonduplicate positive assays obtained while a resident is receiving care in the LTC facility. Laboratory results obtained from outside facilities should not be considered LabID events.



## **CDI Definitions**

- Incident CDI LabID event: the first event ever reported for a resident, OR, a subsequent event reported > 8 weeks after the most recent LabID event reported.
- Recurrent CDI LabID event: any LabID event reported > 2 weeks and ≤ 8 weeks after the most recent LabID event reported.

61



# **CDI Definitions**

- Community-onset (CO) LabID event: date specimen collected is ≤ 3 calendar days from the date of current admission to the facility (i.e., days 1, 2, or 3 of admission).
- Long-term care facility-onset (LO) LabID event: date specimen collected is > 3 calendar days after current admission to the facility (i.e., on or after day 4).



# **CDI Definitions**

Example: Cla	assification o	f CDI LabID Ev	vents as CO o	r LO
Admission date				
June 4	June 5	June 6	June 7	June 8
Day 1	Day 2	Day 3	Day 4	Day 5
Community-on	set (CO)		Long-term care onset (LO)	e facility-

63

Laboratory-identified C. difficile Infection Event	in LTCF

NHSN LTCF MDRO/C. difficile protocol <a href="http://www.cdc.gov/nhsn/PDFs/LTC/LTCF-LabID-Event-Protocol\_FINAL\_8-24-12.pdf">http://www.cdc.gov/nhsn/PDFs/LTC/LTCF-LabID-Event-Protocol\_FINAL\_8-24-12.pdf</a>


Resident name \_\_\_\_\_\_\_Date of admission \_\_\_\_\_\_Date of previous positive *C. difficile* test result \_\_\_\_\_\_\_Date of event \_\_\_\_\_\_(date of specimen collection)


#### C. difficile infection laboratory-identified event (CDI LabID)

- $\hfill\Box$  Individual is receiving care at the LTCF at the time of specimen collection AND
- $\hfill \square$  Stool specimen to be tested conforms to the collection container AND
- $\hfill \square$  A positive C. difficile test result is obtained by at least  $\underline{\sf one}$  of the following laboratory methods
  - o detection of *C. difficile* toxin A or B by enzyme immunoassay (EIA)
  - o detection of a toxin-producing *C. difficile* organism by stool culture or by other laboratory means (e.g., nucleic acid amplification by PCR)

#### AND

 $\ \square$  Any previous *C. difficile* positive test result was obtained >14 days prior to the current test result







# **CDI Data Calculations**

## Total CDI rate/10,000 resident-days

number of CDI LabID events per month/number of resident days per month x 10,000

67



# **CDI Data Calculations**

# CDI LTC facility-onset incidence rate/10,000 resident days

number of all incident LO CDI LabID events per month/number of resident days x 10,000

(This formula excludes recurrent CDI events.)



## **CDI Data Calculations**

#### **Percent community-onset**

number of CO CDI LabID events/total number of CDI LabID events x 100

## **Percent LTC facility-onset**

number of LO CDI LabID events/total number of CDI LabID events x 100

#### **Percent recurrent CDI**

number of recurrent CDI LabID events/total number of CDI LabID events x 100

69



# **DPH HAI Prevention Program**

Gwen Borlaug, CIC, MPH HAI Program Coordinator 1 West Wilson Street Room 272 Madison, Wisconsin 53702 608-267-7711 gwen.borlaug@wi.gov Ashlie Dowdell
HAI Surveillance Coordinator
1 West Wilson Street Room 272
Madison, Wisconsin 53702
608-266-1122
ashlie.dowdell@wi.gov